Published in J Lab Clin Med on November 01, 2003
Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol. Behav Brain Res (2005) 1.45
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol Dis (2009) 1.04
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
Ethyl pyruvate has anti-inflammatory and delayed myocardial protective effects after regional ischemia/reperfusion injury. Yonsei Med J (2010) 0.90
Therapeutic strategies in inflammasome mediated diseases of the liver. J Hepatol (2012) 0.85
Alcoholic liver disease: is it an "extraintestinal" complication of alcohol-induced intestinal injury? J Lab Clin Med (2003) 0.83
Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate. Expert Opin Investig Drugs (2009) 0.82
HMGB1 neutralization is associated with bacterial translocation during acetaminophen hepatotoxicity. BMC Gastroenterol (2014) 0.81
Ethyl pyruvate reduces liver injury at early phase but impairs regeneration at late phase in acetaminophen overdose. Crit Care (2012) 0.81
n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2004) 0.79
Effects of 20 Selected Fruits on Ethanol Metabolism: Potential Health Benefits and Harmful Impacts. Int J Environ Res Public Health (2016) 0.77
Does a combination of opisthorchiasis and ethyl alcohol consumption enhance early cholangiofibrosis, the risk of cholangiocarcinoma? Parasitol Res (2013) 0.77
Effects of Beverages on Alcohol Metabolism: Potential Health Benefits and Harmful Impacts. Int J Mol Sci (2016) 0.76
Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries. J Inflamm (Lond) (2016) 0.75
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med (2007) 5.65
The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med (2004) 5.23
Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA (2002) 4.09
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A (2002) 3.68
Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med (2007) 3.27
HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology (2002) 2.95
Critical care medicine training and certification for emergency physicians. Ann Emerg Med (2005) 2.67
Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30
Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med (2006) 2.27
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Critical care medicine training and certification for emergency physicians. Crit Care Med (2005) 2.12
Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med (2005) 2.11
A comparison of critical care research funding and the financial burden of critical illness in the United States. Crit Care Med (2012) 2.07
Targeting mitochondria. Acc Chem Res (2008) 2.03
Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med (2003) 2.01
Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin (2005) 1.95
Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med (2004) 1.88
The acute inflammatory response in diverse shock states. Shock (2005) 1.83
Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med (2011) 1.77
Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol (2002) 1.70
IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol (2003) 1.70
Cdc42 coordinates proliferation, polarity, migration, and differentiation of small intestinal epithelial cells in mice. Gastroenterology (2013) 1.62
Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg (2006) 1.57
HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol (2005) 1.51
Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther (2004) 1.51
Mitochondrial targeting of selective electron scavengers: synthesis and biological analysis of hemigramicidin-TEMPO conjugates. J Am Chem Soc (2005) 1.50
Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med (2005) 1.49
Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock (2004) 1.46
Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.46
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol (2010) 1.43
Intensive care and emergency medicine: progress over the past 25 years. Chest (2006) 1.43
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol (2006) 1.40
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
Structural requirements for optimized delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J Pharmacol Exp Ther (2006) 1.36
Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock (2002) 1.35
Mast cells regulate homeostatic intestinal epithelial migration and barrier function by a chymase/Mcpt4-dependent mechanism. Proc Natl Acad Sci U S A (2009) 1.34
Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity. Crit Care (2009) 1.32
Blood soluble drag-reducing polymers prevent lethality from hemorrhagic shock in acute animal experiments. Biorheology (2004) 1.29
Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock (2003) 1.28
In silico and in vivo approach to elucidate the inflammatory complexity of CD14-deficient mice. Mol Med (2006) 1.25
Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation (2005) 1.19
Editorial: Hemopexin: newest member of the anti-inflammatory mediator club. J Leukoc Biol (2009) 1.17
Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest (2009) 1.17
In silico models of acute inflammation in animals. Shock (2006) 1.14
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted anti-oxidants. Biochem Pharmacol (2007) 1.13
Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients. Intensive Care Med (2002) 1.12
Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis (2010) 1.11
Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther (2003) 1.10
Increased iNOS activity is essential for pulmonary epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Lung Cell Mol Physiol (2003) 1.10
The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol (2006) 1.08
Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg (2007) 1.06
Red blood cell physiology in critical illness. Crit Care Med (2003) 1.04
Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes in cultured rat enterocytes. Am J Physiol Gastrointest Liver Physiol (2002) 1.03
Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med (2003) 1.02
A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth (2008) 1.02
Bile modulates intestinal epithelial barrier function via an extracellular signal related kinase 1/2 dependent mechanism. Intensive Care Med (2005) 1.02
The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock. Hepatology (2005) 1.01
Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers. J Pharmacol Exp Ther (2003) 1.00
Increased iNOS activity is essential for hepatic epithelial tight junction dysfunction in endotoxemic mice. Am J Physiol Gastrointest Liver Physiol (2003) 0.99
Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol (2009) 0.98
The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro. Biochem Pharmacol (2005) 0.97
Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology (2005) 0.97
Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation. Radiat Res (2007) 0.96
Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis. J Surg Res (2008) 0.96
A single intraperitoneal dose of carbon monoxide-saturated ringer's lactate solution ameliorates postoperative ileus in mice. J Pharmacol Exp Ther (2006) 0.95
Ethyl pyruvate provides durable protection against inflammation-induced intestinal epithelial barrier dysfunction. Shock (2003) 0.95
Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidants. Crit Care Med (2007) 0.95
Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol (2008) 0.92